Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : SNY save search
Response Pharmaceuticals’ Drug Candidate for the Treatment of Antipsychotic-Induced Weight Gain (AIWG) Achieves Primary Endpoint in Phase 1b Clinical Trial
Published: 2024-04-23 (Crawled : 14:30) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
drug candidate treatment for trial response
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
Published: 2024-04-16 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
management company cell nurown trial therapeutics
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
Published: 2024-03-19 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
ibi302 macular trial
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
MLTX | $42.45 -1.85% -1.88% 220K
|
|
| O: 0.51%
H: 0.86%
C: -4.53%
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: 0.0%
nanobody meeting trial
Cervical Cancer Global Clinical Trials Review 2024: Clinical Trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
Published: 2024-03-01 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: -0.43%
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 0.59%
H: 2.06%
C: 2.06%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.28%
H: 0.75%
C: 0.4%
review cancer trials global trial
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
Published: 2024-02-28 (Crawled : 13:00) - globenewswire.com
TNXP | $0.1587 1.21% 1.2% 950K
|
Health Technology
|
| O: 3.26%
H: 2.37%
C: -1.53%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
tnx-1500 pharmaceuticals trial
Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
Published: 2024-02-20 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 2.72%
H: 0.0%
C: -0.8%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 2.53%
H: 0.0%
C: 0.0%
ibi311 disease thyroid eye trial
Sanofi, Denali ALS Candidate Flops in Mid-Stage Trial
Published: 2024-02-19 (Crawled : 13:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
candidate als trial
Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial Efficiency
Published: 2024-02-06 (Crawled : 14:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.25%
H: 0.0%
C: 0.0%
collaboration trial sanofi
Biomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer
Published: 2024-01-24 (Crawled : 15:30) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -3.01%
H: 0.69%
C: -0.75%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
antibody start cancer treatment pharmaceuticals trial
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Published: 2024-01-09 (Crawled : 16:00) - biospace.com/
SKYE | $12.845 -8.45% -9.23% 110K
|
Transportation and Warehousing
|
| O: -7.02%
H: 29.11%
C: 15.56%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
obesity disease kidney bioscience clearance trial
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
Published: 2024-01-09 (Crawled : 00:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.65%
H: 0.69%
C: -0.73%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.0%
H: 0.53%
C: -2.19%
obesity first chinese key trial
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Published: 2023-12-28 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -1.32%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.08%
H: 0.81%
C: -0.19%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.52%
H: 0.72%
C: -0.34%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.35%
H: 1.07%
C: -0.27%
candidate tumors collaboration trial advanced china therapy
Sanofi Axes Lung Cancer ADC After Phase III Trial Failure
Published: 2023-12-21 (Crawled : 18:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
lung axes cancer trial sanofi
Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
Published: 2023-12-21 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
program trial sanofi
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
| Email alert
Add to watchlist
trial potential
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
Published: 2023-12-07 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.19%
H: 0.0%
C: 0.0%
KYMR | $35.18 -1.48% -1.51% 380K
|
Health Technology
|
| O: -0.41%
H: 8.09%
C: 7.64%
kt-474 first dermatitis payment trial therapeutics sanofi
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
Published: 2023-12-07 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.19%
H: 0.0%
C: 0.0%
sarclisa free trial
Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine
Published: 2023-11-13 (Crawled : 17:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.48%
H: 0.0%
C: 0.0%
KYMR | $35.18 -1.48% -1.51% 380K
|
Health Technology
|
| O: 0.14%
H: 3.3%
C: 3.03%
kt-474 publication trial therapeutics results
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474
Published: 2023-10-27 (Crawled : 12:30) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -18.18%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -15.73%
H: 0.0%
C: 0.0%
KYMR | $35.18 -1.48% -1.51% 380K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -5.43%
kt-474 trial therapeutics phase 2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.